Eagle PharmaceuticalsEGRX
13F holders, Q1 2025 (March 31)2holders −7
0new positions
7sold out
$0.98avg. 13F price*
At the end of Q1 2025, 2 institutions reported holding Eagle Pharmaceuticals Inc. (EGRX) in their 13F filings, down 7 from Q4 2024. 0 opened new positions and 7 sold out. The largest holders were Stanley-Laman Group, Ltd. ($12K) and Archer Investment Corp ($343).
- Company
- Eagle Pharmaceuticals Inc.
- CUSIP
- 269796108
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 7 | $33K |
All 13F filers, Q4 2024 → Q1 2025: 66,626 shares sold, net −66,626 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Stanley-Laman Group, Ltd. | 0.00% | No change | 12,000 | $12K |
| Archer Investment Corp | 0.00% | No change | 350 | $343 |
"% of holder's portfolio" is EGRX's weight in each manager's 13F, not the share of Eagle Pharmaceuticals Inc. the manager owns.